Insmed Incorporated (NASDAQ:INSM) Q4 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Pam, and I will be your conference operator today.
Insmed Inc (INSM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Darwin Global Management Abhishek Trehan | 12,960,538 | $894,795,544 | +24% | 84.75% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 5,006,863 | $345,673,822 | +14% | 3.69% |
| 3. | 71,505,000 | $155,248,473 | 0.11% | ||
| 4. | 66,584,000 | $144,306,857 | +8% | 4.16% | |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 1,647,562 | $113,747,680 | +60% | 0.19% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.29 | 10,000 | Director | 10,000 | 2023-05-15 | Filing | |
| $19.29 | 10,000 | Director | 298,615 | 2023-05-15 | Filing | |
| $17.70 | 10,000 | Director | 15,900 | 2022-11-01 | Filing | |
| $17.53 | 20,000 | Director | 281,021 | 2022-10-31 | Filing | |
| $17.69 | 45,000 | Director | 98,265 | 2022-10-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $80.90 | 46 | Officer, Director | 233,924 | 2025-03-03 | Filing | |
| $79.73 | 377 | Officer, Director | 233,970 | 2025-03-03 | Filing | |
| $78.97 | 2,250 | Officer, Director | 234,347 | 2025-03-03 | Filing | |
| $78.20 | 1,486 | Officer, Director | 236,597 | 2025-03-03 | Filing | |
| $76.23 | 2,671 | Officer, Director | 238,083 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,218,973 | $1,257,837,896 | 0.02% | |
| 2. | 16,032,944 | $1,106,914,454 | 0.02% | |
| 3. | 7,116,997 | $491,357,473 | 0.09% | |
| 4. | 6,106,153 | $421,568,803 | 0.01% | |
| 5. | 4,856,249 | $335,275,441 | 0.02% |
News See All
Will Insmed Incorporated’s (INSM) New Drugs be Able to Peak Sales?
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.
10 Best Russell 2000 Stocks to Invest in According to Analysts
The Russell 2000 Index is a widely followed benchmark that tracks the performance of small-cap companies in the United States.
Why INSM Stock Is Advancing Today
Drug maker Insmed (INSM) is rising 6% today after it released on Friday afternoon its estimate of the revenue generated by its Arikayce drug in 2024.
12 Best Multibagger Stocks to Buy Right Now
The US equities continued their upward movement in 2024 and fueled the S&P 500 to record highs.
10 Best Performing Biotech Stocks in 2024
The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and government assistance.
Should You Invest in Insmed Incorporated (INSM)?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter 2024 investor letter.
10 High Growth Healthcare Stocks to Invest in Now
During lean economic times, investing in healthcare stocks is generally regarded as defensive.
Do You Believe in the Growth Potential of Insmed (INSM)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
Insmed Incorporated (NASDAQ:INSM) Q3 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Jeannie, and I will be your conference operator today.